245 Results for "

Complexing agent

" in MedChemExpress (MCE) Product Catalog:
Products (245)

245 Results for "Complexing agent" in MCE Product Catalog:

Cat. No.: HY-L221
626 compounds

Cosmetics are complex mixtures formulated through the rational blending and processing of various natural, synthetic, or extracted raw materials. The ingredients used in cosmetics are diverse in type and functionality. Based on their properties and applications, cosmetic ingredients can generally be classified into two main categories: base materials and auxiliary ingredients. The former constitutes the primary component of cosmetics, accounting for a significant proportion in formulations and serving as the key functional substances. Auxiliary ingredients, on the other hand, play roles in shaping the product, ensuring stability, or imparting color, fragrance, and other specific characteristics.Establishing a systematic ingredient database is of great significance for cosmetic research and development. By analyzing the physicochemical properties (such as oil-water partition coefficients and molecular weight distribution), biological activity mechanisms (such as antioxidant pathways and cellular signaling regulation), and compatibility of ingredients, the database can provide precise guidance for formulation design. This approach helps shorten the development cycle of cosmetic/skincare products and reduces trial-and-error costs.

MCE offers 626 types of cosmetic ingredient compounds, including antioxidants, humectants, emulsifiers, film-forming agents, and more.

Cat. No.: HY-101532
CAS No.: 98169-85-8
Purity:  ≥98.0%
Synonyms: β-CDN3; 6A-deoxy-6A-azido-β-cyclodextrin
Research Areas:  

Others

6A-Azido-6A-deoxy-β-cyclodextrin (β-CDN3) is a site-specifically modified β-cyclodextrin with a single azido group replacing the hydroxyl group at the C6 position. 6A-Azido-6A-deoxy-β-cyclodextrin forms a host-guest inclusion complex with Dexamethasone (HY-14648), localizing the drug within its hydrophobic cavity, which restricts the rotational mobility of the drug and places Dexamethasone in a less polar environment. 6A-Azido-6A-deoxy-β-cyclodextrin acts as a coupling agent to graft β-cyclodextrin onto thermosensitive nanogels via strain-promoted alkyne-azide cycloaddition (SPAAC). 6A-Azido-6A-deoxy-β-cyclodextrin also serves as a click chemistry reagent. It contains an azide group and undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules bearing an alkyne group. It also undergoes strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups .
loading...
    loading...
Cat. No.: HY-L934
122 compounds

CRBN, namely cereblon, is the substrate recognition subunit of the E3 ubiquitin ligase complex in the ubiquitin-proteasome system. A CRBN ligand library refers to a collection of numerous fragments that can specifically bind to the CRBN protein.

These ligands are mostly designed based on validated CRBN-binding warheads and modified through AI-driven molecular generation optimization systems. They not only include classic lenalidomide-derived structures but also cover novel non-lenalidomide scaffolds. After drug-likeness filtering, these ligands exhibit structural diversity and favorable druggable properties. They can be further optimized and modified to facilitate the development of novel molecular glue degraders, accelerate the discovery of molecular glues that induce interactions between CRBN and new substrate proteins, and enable the exploration of novel CRBN substrates for identifying previously unknown CRBN-binding proteins.

MCE compiles 122 fragments that can specifically bind to the CRBN protein, with molecular weights ranging from 200 to 500. Compounds developed based on the library ligands target multiple disease targets such as cancer and autoimmune diseases, further advancing the development of Molecular Glues and PROTACs therapeutic agents.

Cat. No.: HY-162775
CAS No.: 50566-97-7
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

TST1N-224 is a potent response regulator VraRC inhibitor. TST1N-224 can disrupt VraRC-DNA complex formation (IC50=60.2 μM). TST1N-224 exhibits interference with VraRC binding to its cognate DNA through a fast-on-fast-off binding mechanism (KD=23.4 μM). TST1N-224 predominantly interacts with the α9- and α10-helixes of the DNA-binding domain of VraR. TST1N-224 inhibits the growths of S. aureus (SA; MIC>126 μM), Methicillin-resistant S. aureus (MRSA; MIC>126 μM), and Vancomycin-intermediate S. aureus (VISA; MIC=63 μM). TST1N-224, an antimicrobial agent, evidently enhances the susceptibility of VISA to both Vancomycin (HY-B0671) and Methicillin (HY-B0974) .
loading...
    loading...
Cat. No.: HY-170524
CAS No.: 3052313-73-9
Research Areas:  

Infection

TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
loading...
    loading...